Yaquine Mechelfekh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yaquine Mechelfekh has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Alain Ramassamy
1 shared publicationAlexandre Butelet
1 shared publicationAudrey Pontrucher
Laboratory of Hematology, CHU d'Angers Université d'Angers Angers France
1 shared publicationAurélie Montmartin
1 shared publicationBenoit Guillet
1 shared publication- Brigitte Tardy-Poncet
CHU and Université Jean Monnet, Saint-Etienne, Saint Etienne, France
1 shared publication
Latest Publications
- Open Access
- 13 June 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (4)
Safety of von Willebrand factor substitution for neuraxial anesthesia in women with persistent von Willebrand deficiency at delivery
- 13 June 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (4)
Open AccessSafety of von Willebrand factor substitution for neuraxial anesthesia in women with persistent von Willebrand deficiency at delivery
- Open Access
- 3 October 2023
- Published by Elsevier in Bulletin du Cancer
- Vol. 110 (12) , 1232-1233
Ivosidenib–azacitidine dans les leucémies aiguës myéloïdes avec mutation IDH1 R132
- 3 October 2023
- Published by Elsevier in Bulletin du Cancer
- Vol. 110 (12) , 1232-1233
Open AccessIvosidenib–azacitidine dans les leucémies aiguës myéloïdes avec mutation IDH1 R132
- Open Access
- 5 May 2023
- Published by Wiley in British Journal of Haematology
- Vol. 202 (1) , 168-172
Obinutuzumab‐induced acute thrombocytopenia: Report of two cases and review of literature
Summary: Obinutuzumab (GA101) is a humanized anti‐CD20 monoclonal antibody used in the treatment of B‐cell malignancies. Under rare occasions, obinutuzumab may induce acute and severe thrombocytopenia. However, little is known about this side effect, referred to as “obinutuzumab‐induced acute thrombocytopenia” (OIAT). Here, we report 2 cases of OIAT and review the literature to inform the management and outcome of this rare but life‐threatening complication. The first case is a 74 year‐ old woman who was treated with obinutuzumab‐Cyclophosphamide, Vincristine, Prednisone (CVP) for a previously untreated follicular lymphoma. This patient experienced an acute thrombocytopenia with a drop in her platelet count from 376 G/L to 3 G/L the day after treatment. The second case is a 44 year‐ old woman who was treated with obinutuzumab as a pre‐treatment dose (day‐8) before glofitamab infusion as a 4th line therapy for mantle cell lymphoma. This patient experienced an acute thrombocytopenia with a drop in her platelet count from 76 G/L (due to splenomegaly and bone marrow involvement) to 3 G/L the day after treatment. OIAT is a rare but life‐threatening complication. Physicians should be aware of this adverse event to optimally detect and treat this complication.
- 5 May 2023
- Published by Wiley in British Journal of Haematology
- Vol. 202 (1) , 168-172
Open AccessObinutuzumab‐induced acute thrombocytopenia: Report of two cases and review of literature
Summary: Obinutuzumab (GA101) is a humanized anti‐CD20 monoclonal antibody used in the treatment of B‐cell malignancies. Under rare occasions, obinutuzumab may induce acute and severe thrombocytopenia. However, little is known about this side effect, referred to as “obinutuzumab‐induced acute thrombocytopenia” (OIAT). Here, we report 2 cases of OIAT and review the literature to inform the management and outcome of this rare but life‐threatening complication. The first case is a 74 year‐ old woman who was treated with obinutuzumab‐Cyclophosphamide, Vincristine, Prednisone (CVP) for a previously untreated follicular lymphoma. This patient experienced an acute thrombocytopenia with a drop in her platelet count from 376 G/L to 3 G/L the day after treatment. The second case is a 44 year‐ old woman who was treated with obinutuzumab as a pre‐treatment dose (day‐8) before glofitamab infusion as a 4th line therapy for mantle cell lymphoma. This patient experienced an acute thrombocytopenia with a drop in her platelet count from 76 G/L (due to splenomegaly and bone marrow involvement) to 3 G/L the day after treatment. OIAT is a rare but life‐threatening complication. Physicians should be aware of this adverse event to optimally detect and treat this complication.